ADVERSE EFFECT VERSUS QUALITY CONTROL OF THE FUENZALIDA-PALACIOS ANTIRABIES VACCINE

• Published in: Revista do Instituto de Medicina Tropical de São Paulo
• Main Author: Yeda L. NOGUEIRA
• Format: Article in Journal/Newspaper
• Language: English
• Published: Universidade de São Paulo (USP) 1998
• Subjects: Adverse effect; Antirabies vaccine; Fuenzalida-Palacios; HDVC; Albumin; Crossed immunoelectrophoresis; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic; Barré; Ela; Fuenzalida
• Online Access: https://doi.org/10.1590/S0036-46651998000500006; https://doaj.org/article/a9f498933fe045e8b76b82a7930c6cdb

We evaluated the components of the Fuenzalida-Palacios antirabies vaccine, which is till used in most developing countries in human immunization for treatment and prophylaxis. This vaccine is prepared from newborn mouse brains at 1% concentration. Even though the vaccine is considered to have a low myelin content, it is not fully free of myelin or of other undesirable components that might trigger adverse effects after vaccination. The most severe effect is a post-vaccination neuroparalytic accident associated with Guillain-Barré syndrome. In the present study we demonstrate how the vaccines produced and distributed by different laboratories show different component patterns with different degrees of impurity and with varying protein concentrations, indicating that production processes can vary from one laboratory to another. These differences, which could be resolved using a better quality control process, may affect and impair immunization, with consequent risks and adverse effects after vaccination. We used crossed immunoelectrophoresis to evaluate and demonstrate the possibility of quality control in vaccine production, reducing the risk factors possibly involved in these immunizing products. Avaliamos os componentes da vacina anti-rábica tipo Fuenzalida-Palacios que é ainda utilizada na maioria dos países em desenvolvimento na imunização humana para o tratamento profilático. Essa vacina é feita em cérebros de camundongos neonatos diluida a 1%, apesar de ser considerada uma vacina com pouco teor de mielina, no entanto ela não é totalmente livre de mielina, bem como de outros componentes indesejáveis que podem desencadear efeitos adversos a vacinação, o efeito mais grave está relacionado com o acidente neuroparalítico pós vacinal associado a síndrome de Guillain Barré. Neste trabalho demonstramos como as vacinas produzidas e distribuidas pelos diversos laboratórios produtores apresentam padrões diferentes de seus componentes com diversos graus de impurezas e com concentrações proteicas também variadas, ...